We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

The country's pharma lobby groups have been seeking a two-year extension to the deadline, saying that much time is needed for improving infrastructure, increasing manpower and training. The lobby ...

Jefferies analyst Stephen Barker maintained a Hold rating on Astellas Pharma (ALPMF – Research Report) yesterday and set a price target of Yen1,700.00. The company’s shares closed last ...

Cancer is well represented in the Astellas Pharma portfolio and pipeline, but the drugmaker has made diversification a key part of its growth strategy. Newer products in its drug lineup include a ...

NEW YORK, Jan 23 (Reuters) - Purdue Pharma and its Sackler family owners have reached a new $7.4 billion settlement to resolve thousands of lawsuits alleging that the pain medication OxyContin ...

Astellas Pharma Inc. can’t enforce a patent-infringement settlement with MSN Laboratories Pvt. Ltd. over a generic version of the overactive-bladder drug Myrbetriq because the deal was never signed, a ...

Aaaaaa Aaaaaaa Aaaa 113.80 +22.98% ...

Continued improvements to downtown, including expanded outdoor dining, are strong on the radar for Northbrook officials as they enter 2025. “One of the cool things we did in 2023 was a survey of ...

It is an antibody-drug conjugate (ADC) that acts by targeting nectin-4. Astellas Pharma (Astellas) discovers, develops, manufactures, and commercializes a wide range of pharmaceuticals. The company’s ...

ASP-3082 is under clinical development by Astellas Pharma and currently in Phase I for Pancreatic Ductal Adenocarcinoma. According to GlobalData, Phase I drugs for Pancreatic Ductal Adenocarcinoma ...